Table 3.

Clinical outcomes in relation to AGR after CRP stratification

AGR	Prevalence (%)	Crude OR (95% CI)	Adjusted OR (95% CI)
CRP ≤0.1 mg/dL (n=158)
Clinical remission
Low AGR	10/19 (52.6)	1.00	1.00
Moderate AGR	24/44 (54.6)	1.08 (0.36–3.20)	1.51 (0.43–5.42)
High AGR	28/41 (68.3)	1.94 (0.63–6.00)	2.52 (0.66–9.92)
Very high AGR	36/54 (66.7)	1.80 (0.62–5.27)	3.11 (0.83–12.27)
P for trend			0.90
Complete MH (MES 0)
Low AGR	4/19 (21.1)	1.00	1.00
Moderate AGR	10/44 (22.7)	1.10 (0.31–4.53)	1.59 (0.39–7.55)
High AGR	16/41 (39.0)	2.40 (0.72–9.59)	3.45 (0.84–16.70)
Very high AGR	20/54 (37.0)	2.21 (0.69–8.56)	4.38 (1.06–21.77)
P for trend			0.017
MH (MES 0–1)
Low AGR	15/19 (79.0)	1.00	1.00
Moderate AGR	27/44 (61.4)	0.42 (0.11–1.40)	0.40 (0.09–1.46)
High AGR	31/41 (75.6)	0.83 (0.20–2.94)	0.62 (0.13–2.55)
Very high AGR	39/54 (72.2)	0.69 (0.18–2.28)	0.56 (0.12–2.20)
P for trend			0.90
CRP >0.1 mg/dL (n=115)
Clinical remission
Low AGR	15/48 (31.3)	1.00	1.00
Moderate AGR	14/26 (53.9)	2.57 (0.97–7.00)	2.89 (0.97–9.10)
High AGR	21/27 (77.8)	7.70 (2.71–24.73)	11.09 (3.17–45.38)
Very high AGR	9/14 (64.3)	3.96 (1.17–14.86)	4.76 (1.13–22.98)
P for trend			0.38
Complete MH (MES 0)
Low AGR	5/48 (10.4)	1.00	1.00
Moderate AGR	6/26 (23.1)	2.58 (0.70–9.94)	2.44 (0.61–10.32)
High AGR	7/27 (25.9)	3.01 (0.86–11.31)	3.27 (0.79–14.94)
Very high AGR	4/14 (28.6)	3.44 (0.74–15.46)	3.12 (0.57–17.27)
P for trend			0.11
MH (MES 0–1)
Low AGR	21/48 (43.8)	1.00	1.00
Moderate AGR	14/26 (53.9)	1.50 (0.58–3.97)	1.06 (0.35–3.16)
High AGR	16/27 (59.3)	1.87 (0.73–4.97)	1.45 (0.47–4.56)
Very high AGR	9/14 (64.3)	2.31 (0.69–8.51)	1.80 (0.41–8.71)
P for trend			0.38

AGR, albumin to globulin ratio; CRP, C-reactive protein; OR, odds ratio; CI, confidence interval; MH, mucosal healing; MES, Mayo endoscopic subscore.

Adjusted for age, sex, use of prednisolone, body mass index, onset age, use of tumor necrosis factor-α monoclonal antibody, and disease extent.